SLC13A5 and metabolic dysfunction-associated steatotic liver disease: The perturbation of SLC13A5 expression and/or activity is associated with non-alcoholic fatty liver disease, obesity, insulin resistance, cell proliferation, and early infantile epileptic encephalopathy.